GLP-1 Curve

If you stop, what comes back

Three trials deliberately took people off these drugs and kept weighing them. Across all three, roughly two-thirds of the lost weight returned within a year. Here is what that arithmetic looks like on your numbers.

Projected weight over 12 months after stopping, against staying on treatment
If you stop now If you stay on
3 months after stopping
6 months after stopping
12 months after stopping
12 months if you stayed on instead
Difference at 12 months
What staying on would cost

What the withdrawal trials actually did

In the STEP 1 extension, participants who had lost about 17% of their body weight on semaglutide came off the drug and were followed for another year. A year later they had regained roughly two-thirds of it, sitting about 6% below where they had started. STEP 4 ran the cleaner version of the experiment: everyone got the drug for 20 weeks, then half were switched to placebo. Over the next 48 weeks the placebo group gained about 7% while the group that stayed on lost a further 8%.

SURMOUNT-4 did the same with tirzepatide. After 36 weeks the group averaged about 21% below baseline; the half switched to placebo regained about 14 percentage points over the next year, while the half who continued lost another 5 or so.

All three trials point the same way and the arithmetic is the same for every drug in this class: these medications treat the condition while they are being taken. Stopping is not a graduation.

What the trials do not tell you

They do not tell you that regain is inevitable for you specifically. The trial participants who came off had no structured maintenance programme; they simply stopped and were measured. Longer-running observational work on people who have maintained large losses without drugs — the National Weight Control Registry being the best known — consistently finds high physical activity, regular self-weighing and consistent eating patterns among those who hold their loss. That is association rather than proof, and none of those studies were done in people coming off a GLP-1.

What is fair to say: the regain figures above describe stopping with nothing in place. They are a reasonable default expectation, not a sentence.

They also cannot tell you what a lower dose would do, and this page deliberately does not model that. Dose is a decision for the person who wrote your prescription.

This is an arithmetic tool built on published group averages, not medical advice and not a prediction for any individual. It is not a reason to stop, continue, or change a prescription — that decision belongs with the clinician who prescribed it, and stopping these medications is something to plan with them rather than alone. Trial populations differ from any one person, and regain varies widely.